



ANNUAL REPORT

Fiscal Year 2015-2016





A Letter from our Executive Director



What an auspicious year. We've accomplished a great deal and there is so much more to do. Our research portfolio continues to grow with trials of new interventions for methamphetamine addiction and for HIV prevention that carry such exciting potential. Our clinical practice has expanded too, with a larger team of clinicians, both physicians and psychologists, and new services. Achievements in the areas of evaluation, training and capacity building now place us firmly as leaders with a new grant from the Health Resources and Services Administration's Special Projects of National Significance (SPNS). Yet the guiding mission at CBAM remains to leverage the power of science to reduce suffering. I have the immense privilege of working with a group of people who share that goal; people with great minds and big hearts; people dedicated equally to scientific rigor, excellence in patient care, and service to the community.

Looking ahead, we remain focused on growth as we expand our UCLA Vine Street Clinic in Hollywood to meet increased demand. This will include the build out of additional exam rooms and lab space, upgrades to our phone and IT systems, new workspace for staff and general facility improvements. CBAM continues to bring cutting-edge, potent and advanced medication research opportunities for addiction and HIV prevention to the communities that need them most. Although the UCLA campus has the most advanced facilities in the world, it's location is inconvenient and often inhospitable for those living with addictions and who need HIV prevention. Providing our services within the communities we serve, we improve the chances that those most in need can access these resources, an approach being recognized around the world. This year we hosted guests from Vietnam, China and Australia working to duplicate this model and we now have an exciting collaboration at the University of Cape Town.

It's vital to note that none of this work would be possible without the support and leadership of our home department here at UCLA, the Department of Family Medicine. Here's to a year of health and continued achievements.



CBAM faculty, staff and colleagues at a Los Angeles County HIV Commission meeting.



Hosting a visitor from Vietnam to discuss conducting research in a community setting.




Members of the UCLA Vine Street Clinic's HIV Prevention Trials Network (HPTN) study team with site monitor's from the network.



About CBAM

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illness, especially in communities with health disparities.

As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.



HIV/AIDS

- Los Angeles is the 2nd largest epicenter for AIDS cases in the U.S. (behind New York)
- People aged 13-29 make up 39% of all new HIV infections
- Locally, 84% of AIDS cases are among MSM, with a disproportionate number of new cases occurring in Black and Latino MSM
- PrEP (pre-exposure prophylaxis) refers to a medication that can be taken daily by an HIV negative person to help prevent HIV acquisition
- Daily PrEP use can lower the risk of acquiring HIV from sex by more than 90%

Addiction

- Addiction is a chronic, recurring disease that often requires multiple approaches (both medical and behavioral) to treat effectively
- According to SAHMSA's 2015 national survey, 21.5 million Americans aged 12 or older (8.1%) are addicted to alcohol or drugs (not including tobacco)
- Fewer than 1 in 10 people who need treatment actually get that care
- Primary care physicians (PCPs) are the first and sometimes only point of contact for patients, yet addiction is only recently receiving attention as a problem in primary care offices



Research

In pursuit of our mission, CBAM scientists, clinicians and staff conduct research on medical and behavioral approaches for prevention and treatment of chronic illness, with particular focus on addiction and HIV. We stress the values of integrity and scientific rigor in all that we do. We work closely with the communities we serve to ensure that we provide outstanding care that is respected and valued. Below are just a few of our research highlights from the past year.



HIV Prevention science has produced game-changing advances over the past few years. While condoms coupled with voluntary counseling and testing prevent the spread of HIV for many, this strategy is not always enough. Some in our most vulnerable groups, like those with substance use and mental health disorders, cannot maintain 100% condom use and regular HIV testing. An approach called Pre-Exposure Prophylaxis (PrEP) can now be used to prevent HIV infection. PrEP means taking one pill a day (Truvada) to help HIV-negative people stay uninfected, even if exposed to HIV. CBAM scientists and colleagues are now studying additional, longer-lasting medication alternatives to a

daily pill. In one trial, HVTN704/HPTN 085 (the AMP Study) we are testing the safety and early efficacy of a broadly neutralizing antibody, VCR-01. This approach, which works something like a vaccine, involves every other month infusions of antibodies that can kill over 80% of HIV strains. A second study, HPTN 083, is set to start soon and will compare daily Truvada to a long-lasting injectable medication for HIV prevention. We also continue cohort study (mSTUDY), which will help us understand the direct interactions of substance use with HIV transmission dynamics in men who have sex with men (MSM) of color. More than 300 participants have been enrolled in that study to date across two sites.

We continue to lead the science in development of medications for methamphetamine abuse. Additionally, CBAM scientists expanded their involvement in addiction research to alcohol dependence with a clinical trial funded by the National Institute on Alcohol Abuse and Alcoholism. The purpose of the trial is to test whether *HORIZANT*® (gabapentin enacarbil) is useful and safe for treating alcohol use disorders. This study was conducted at the UCLA Family Health Center, our Department's primary care clinic and at the UCLA Clinical Translational Research Center. Bringing research into a primary care setting allows for a greater transfer of knowledge and acceptance of research among care providers and greater access to patients in need of nontraditional care.





Publications

In FY 2015-2016, CBAM faculty and staff co-authored 22 peer-reviewed articles in publications such as the *Journal of Clinical Psychopharmacology*, *American Journal of Public Health* and *AIDS Care*, just to name a few. They covered topics ranging from pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain, to the use of technology to address substance use in the context of HIV, to various outcomes of our methamphetamine clinical trials.

We also participated in the HPTN 073 writing retreat, held at Charles R Drew University. The retreat gathered protocol leaders, site leaders, Black Caucus members, lab and data leaders, and advocates together to review the first cut of findings from the HPTN 073 trial of PrEP uptake and use by Black MSM.




CBAM Executive Director Steve Shoptaw and our community liaison, Christopher Hucks-Ortiz are featured in the picture to the right, standing 2nd and 3rd from the left in the back row.

UCLA Vine Street Clinic

The UCLA Vine Street Clinic (UVSC) was established to study the diffusion of HIV in networks of methamphetamine users. Since that time, it has served as a site for clinical trials, behavioral research, and direct services focusing on the treatment of addiction, HIV prevention, and the intersection of the two. It is also a meeting place for outside groups including a weekly recovery group and multiple community advisory boards. It is unique in its location, bringing the best in academia from UCLA into a transitional neighborhood of predominately working poor, which has additionally been designated as a medically underserved community.



The UCLA Vine Street Clinic is home to some of the world's most cutting-edge research. Our small but dedicated team continues to find ways to do more every year with a steady increase in the number of visits (patient encounters) that we see each year, with nearly 10,000 total visits since our inception. As Dr. Shoptaw mentioned in his opening letter, we will be expanding the clinic this coming year by adding another 1,300 square feet of space, including the build out of additional exam rooms and lab space, upgrades to our phone and IT systems, and general facility improvements. See page 9 to find out how you can help with this endeavor!





International Reach

CBAM's work continues to garner international attention. In March, Dr. Shoptaw was invited to address the United Nations Office on Drugs and Crime. The meeting, entitled Science Addressing Drugs and HIV: State of the Art An Update, was held in Vienna, Austria. Dr. Shoptaw spoke on the role of antiretrovirals (ARVs) in HIV prevention, treatment and care for people who inject drugs.



CBAM also started a collaboration with the Department of Psychiatry at the University of Cape Town (UCT). The inaugural study aims to provide some of the first fMRI images from methamphetamine-dependent individuals that describe the neuroscientific mechanism of action for contingency management as a behavioral treatment. The work is the first in South Africa to implement contingency management as a treatment for methamphetamine addiction. Findings are already guiding ways to adapt contingency management for use in Cape Town, which is in the midst of an epidemic of methamphetamine addiction in the setting of an uncontrolled, generalized HIV epidemic. UCT recognized the contributions of Dr. Shoptaw in teaching and research by giving him an honorary professor title in the Department of Psychiatry and Mental Health.

CBAM is also bringing international collaborators to Los Angeles. Dr. Brendan Quinn is a Research Officer in the Centre for Population Health at the Burnet Institute in Melbourne, Australia. He won a highly prestigious Fulbright Scholar award and is now work alongside Dr. Shoptaw and the CBAM team to learn about our work with methamphetamine (MA) and how to engage MA users to reduce their use and other high risk behaviors. While this topic has been explored in depth in the United States, such research is rare in Australia where methamphetamine use has tripled over the past five years.






Clinical Services

CBAM is a leader in the implementation of scientifically-evaluated behavioral and addiction medicine services in primary care and community-based settings.

In FY 2015-2016, CBAM clinicians managed over 3,300 patient visits (encounters) across multiple set-



tings including primary and specialty clinics and private offices. This continues a steady increase from previous years. Services provided include assessment and treatment of patients presenting with behavioral, psychiatric, and addiction-related disorders. That's in addition to the more than 1,700 visits this year in our research clinic. CBAM also expanded its behavioral support services to include substance use screening, evaluation, and motivational interviewing, as well as case coordination for UCLA athletes.

Training

CBAM's training activities seek to inspire the next generation of clinicians, researchers, and public health professionals to use evidence-based interventions that have been proven to work.

This year, CBAMer Ron Brooks, PhD, was awarded a grant from HRSA as part of their Special Projects of National Significance. The Social Media Evaluation and Technical Assistance Center (ETAC) provides leadership and technical assistance to demonstration sites around the country (see map) that are implementing social media-based interventions to engage and retain HIV-positive youth and young adults in HIV medical care and to facilitate adherence to HIV medications.



We again hosted two interns from the NIDA's summer research program for underrepresented undergraduate students. CBAM has been participating in this program for nearly a decade and we are always impressed and encouraged by the level of intelligence and curiosity these interns bring with them.

In February, CBAM worked with colleagues at the UCLA Behavioral Epidemiology Research Group to organize a day-long conference focused on "Advancing the Field of Biobehavioral Substance Use Measurement for HIV Positive and At-risk Populations". Attendees included leaders in the field from UCLA, Columbia University, Johns Hopkins, UCSF, private industry and other universities.



CENTER FOR BEHAVIORAL & ADDICTION MEDICINE
Financial Statement for Fiscal Year 2015/2016
 (July 1, 2015 through June 30, 2016)

INCOME	Permanently Restricted	Temporarily Restricted	Unrestricted	Total	FY 2014/2015
Federal Contracts & Grants	\$ 3,472,341	\$ 391,179		\$ 3,863,520	\$ 2,509,756
State/Local Contracts & Grants				\$ -	\$ 125,745
Subcontracts Corporations	\$ 201,871			\$ 201,871	\$ 320,169
Foundations				\$ -	\$ -
Individuals				\$ -	\$ -
UC Funds	\$ 220,158		\$ 29,653	\$ 249,811	\$ 183,538
Clinical Services Income		\$ 609,388		\$ 609,388	\$ 422,658
TOTAL INCOME	\$ 3,894,370	\$ 1,000,567	\$ 29,653	\$ 4,924,590	\$ 3,561,866
EXPENSES					
Academic Salaries				\$ 880,915	\$ 726,977
Staff Salaries				\$ 1,026,421	\$ 1,126,668
Fringe Benefits				\$ 752,582	\$ 752,063
Stipends - Postdoctoral Fellows				\$ 3,640	\$ 97,492
Stipends - Interns				\$ 9,355	\$ 6,000
Consultants				\$ 17,862	\$ 12,139
Tuition - Postdoctoral Fellows				\$ -	\$ 1,005
Employee Training/Certifications/Licenses/Memberships				\$ 990	\$ 2,970
Subawards				\$ 32,062	\$ 14,265
Space Rental				\$ 150,237	\$ 155,915
Communications				\$ 35,535	\$ 35,033
Clinic Operations				\$ 27,912	\$ 42,961
General Supplies & Equipment				\$ 1,130	\$ 7,757
Computers, Software & Computer Supplies				\$ 16,326	\$ 16,185
Medical Supplies				\$ 59,562	\$ 44,294
Project-Related Supplies				\$ 26,547	\$ 18,393
Travel and Events				\$ 99,441	\$ 45,564
Postage/Courier				\$ 8,503	\$ 10,994
Print/Copy Services				\$ 4,634	\$ 6,277
Recruitment Ads				\$ 60,459	\$ 67,010
Lab Services				\$ 68,826	\$ 59,015
Pharmacy				\$ 9,658	\$ 23,750
Participant Incentives				\$ 61,731	\$ 45,198
Miscellaneous				\$ 7,630	\$ 6,398
Indirect Charges				\$ 604,044	\$ 581,947
TOTAL EXPENSES				\$ 3,966,002	\$ 3,906,271
NET INCOME (LOSS) YTD*				\$ 958,587	\$ (344,405)

This document was generated internally. It is not an audited financial statement.

**Over 95% of the net balance is restricted project funding that will carryover into the next fiscal year.*




Help Us Grow



Our research portfolio grew significantly this year. Now it's time to grow our clinic! We are seeking \$100,000 in donations to pay for the build out of new space—new walls, new wires, new furniture and medical equipment. CBAM is unique in that we bring research directly into the communities we serve. Help us to serve more by donating today. Naming opportunities are available. For every donation of \$10,000, a room in the clinic will be named after the donor.

Visit us at <http://www.uclacbam.org/about-us/donate/> to make your tax deductible donation or call (310) 794-0619 ext. 229 to speak with our Administrative Director. 93.5% of the money you give will go directly to serve our mission.



Contact Us!

UCLA Center for Behavioral &
Addiction Medicine
10880 Wilshire Blvd., Ste. 1800
Los Angeles, CA 90024
(310) 794-0619
cbam@mednet.ucla.edu
cbam.ucla.edu